Logo image of STIM

NEURONETICS INC (STIM) Stock Fundamental Analysis

USA - NASDAQ:STIM - US64131A1051 - Common Stock

2.05 USD
-0.11 (-5.09%)
Last: 11/13/2025, 2:01:03 PM
Fundamental Rating

2

STIM gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. STIM may be in some trouble as it scores bad on both profitability and health. STIM is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

STIM had negative earnings in the past year.
STIM had a negative operating cash flow in the past year.
STIM had negative earnings in each of the past 5 years.
STIM had a negative operating cash flow in each of the past 5 years.
STIM Yearly Net Income VS EBIT VS OCF VS FCFSTIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of STIM (-36.24%) is worse than 60.32% of its industry peers.
With a Return On Equity value of -179.75%, STIM is not doing good in the industry: 69.31% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -36.24%
ROE -179.75%
ROIC N/A
ROA(3y)-29.62%
ROA(5y)-29.17%
ROE(3y)-103.71%
ROE(5y)-91.08%
ROIC(3y)N/A
ROIC(5y)N/A
STIM Yearly ROA, ROE, ROICSTIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

Looking at the Gross Margin, with a value of 56.15%, STIM is in line with its industry, outperforming 53.44% of the companies in the same industry.
In the last couple of years the Gross Margin of STIM has remained more or less at the same level.
STIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y-0.84%
STIM Yearly Profit, Operating, Gross MarginsSTIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

2

2. Health

2.1 Basic Checks

STIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
STIM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, STIM has more shares outstanding
Compared to 1 year ago, STIM has an improved debt to assets ratio.
STIM Yearly Shares OutstandingSTIM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
STIM Yearly Total Debt VS Total AssetsSTIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

STIM has an Altman-Z score of -3.57. This is a bad value and indicates that STIM is not financially healthy and even has some risk of bankruptcy.
STIM's Altman-Z score of -3.57 is on the low side compared to the rest of the industry. STIM is outperformed by 65.08% of its industry peers.
STIM has a Debt/Equity ratio of 2.05. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of STIM (2.05) is worse than 83.60% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.05
Debt/FCF N/A
Altman-Z -3.57
ROIC/WACCN/A
WACC8.83%
STIM Yearly LT Debt VS Equity VS FCFSTIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

STIM has a Current Ratio of 2.02. This indicates that STIM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.02, STIM is doing worse than 62.96% of the companies in the same industry.
STIM has a Quick Ratio of 1.84. This is a normal value and indicates that STIM is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.84, STIM perfoms like the industry average, outperforming 48.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 1.84
STIM Yearly Current Assets VS Current LiabilitesSTIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

STIM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.33%, which is quite impressive.
STIM shows a small growth in Revenue. In the last year, the Revenue has grown by 4.96%.
STIM shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.63% yearly.
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.45%
Revenue 1Y (TTM)4.96%
Revenue growth 3Y10.63%
Revenue growth 5Y3.63%
Sales Q2Q%101.28%

3.2 Future

The Earnings Per Share is expected to grow by 18.70% on average over the next years. This is quite good.
Based on estimates for the next years, STIM will show a very strong growth in Revenue. The Revenue will grow by 25.79% on average per year.
EPS Next Y57.31%
EPS Next 2Y29.23%
EPS Next 3Y21.45%
EPS Next 5Y18.7%
Revenue Next Year109.15%
Revenue Next 2Y52.89%
Revenue Next 3Y38.05%
Revenue Next 5Y25.79%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
STIM Yearly Revenue VS EstimatesSTIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M
STIM Yearly EPS VS EstimatesSTIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for STIM. In the last year negative earnings were reported.
Also next year STIM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STIM Price Earnings VS Forward Price EarningsSTIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STIM Per share dataSTIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as STIM's earnings are expected to grow with 21.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.23%
EPS Next 3Y21.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for STIM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEURONETICS INC

NASDAQ:STIM (11/13/2025, 2:01:03 PM)

2.05

-0.11 (-5.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)03-02 2026-03-02/amc
Inst Owners27.71%
Inst Owner Change2.17%
Ins Owners6.38%
Ins Owner Change5.84%
Market Cap135.55M
Revenue(TTM)74.89M
Net Income(TTM)-48.80M
Analysts82.22
Price Target6.63 (223.41%)
Short Float %14.83%
Short Ratio4.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-78.26%
Min EPS beat(2)-91.81%
Max EPS beat(2)-64.71%
EPS beat(4)0
Avg EPS beat(4)-74.53%
Min EPS beat(4)-91.81%
Max EPS beat(4)-54.06%
EPS beat(8)2
Avg EPS beat(8)-34.91%
EPS beat(12)6
Avg EPS beat(12)-13.79%
EPS beat(16)8
Avg EPS beat(16)-9.34%
Revenue beat(2)2
Avg Revenue beat(2)4.68%
Min Revenue beat(2)1.52%
Max Revenue beat(2)7.85%
Revenue beat(4)3
Avg Revenue beat(4)4.16%
Min Revenue beat(4)-5.05%
Max Revenue beat(4)12.31%
Revenue beat(8)4
Avg Revenue beat(8)0.37%
Revenue beat(12)7
Avg Revenue beat(12)1.37%
Revenue beat(16)10
Avg Revenue beat(16)1.33%
PT rev (1m)0%
PT rev (3m)-4.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-90%
EPS NY rev (1m)0%
EPS NY rev (3m)-60.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.22
P/FCF N/A
P/OCF N/A
P/B 4.99
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS1.68
BVpS0.41
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -36.24%
ROE -179.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.15%
FCFM N/A
ROA(3y)-29.62%
ROA(5y)-29.17%
ROE(3y)-103.71%
ROE(5y)-91.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y-0.84%
F-Score3
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 2.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.15%
Cap/Sales 0.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.02
Quick Ratio 1.84
Altman-Z -3.57
F-Score3
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)129%
Cap/Depr(5y)137.27%
Cap/Sales(3y)3.43%
Cap/Sales(5y)3.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.45%
EPS Next Y57.31%
EPS Next 2Y29.23%
EPS Next 3Y21.45%
EPS Next 5Y18.7%
Revenue 1Y (TTM)4.96%
Revenue growth 3Y10.63%
Revenue growth 5Y3.63%
Sales Q2Q%101.28%
Revenue Next Year109.15%
Revenue Next 2Y52.89%
Revenue Next 3Y38.05%
Revenue Next 5Y25.79%
EBIT growth 1Y-28.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.12%
EBIT Next 3Y22.25%
EBIT Next 5Y16.54%
FCF growth 1Y1.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.53%
OCF growth 3YN/A
OCF growth 5YN/A

NEURONETICS INC / STIM FAQ

What is the ChartMill fundamental rating of NEURONETICS INC (STIM) stock?

ChartMill assigns a fundamental rating of 2 / 10 to STIM.


Can you provide the valuation status for NEURONETICS INC?

ChartMill assigns a valuation rating of 1 / 10 to NEURONETICS INC (STIM). This can be considered as Overvalued.


Can you provide the profitability details for NEURONETICS INC?

NEURONETICS INC (STIM) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for STIM stock?

The Earnings per Share (EPS) of NEURONETICS INC (STIM) is expected to grow by 57.31% in the next year.